Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Frontiers in Cell and Developmental Biology,
Год журнала:
2024,
Номер
12
Опубликована: Июль 16, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD),
previously
known
as
non-alcoholic
fatty
(NAFLD),
is
the
most
common
disorder
worldwide,
with
an
estimated
global
prevalence
of
more
than
31%.
steatohepatitis
(MASH),
formerly
(NASH),
a
progressive
form
MASLD
characterized
by
hepatic
steatosis,
inflammation,
and
fibrosis.
This
review
aims
to
provide
comprehensive
analysis
extrahepatic
manifestations
MASH,
focusing
on
chronic
diseases
related
cardiovascular,
muscular,
renal
systems.
A
systematic
published
studies
literature
was
conducted
summarize
findings
systemic
impacts
MASH.
The
focused
association
MASH
metabolic
comorbidities,
cardiovascular
mortality,
sarcopenia,
kidney
disease.
Mechanistic
insights
into
concept
lipotoxic
inflammatory
"spill
over"
from
MASH-affected
were
also
explored.
are
highly
associated
(50%-80%)
other
comorbidities
such
impaired
insulin
response,
type
2
diabetes,
dyslipidemia,
hypertriglyceridemia,
hypertension.
Furthermore,
90%
obese
patients
diabetes
have
Data
suggest
that
in
middle-aged
individuals
(especially
those
aged
45-54),
independent
risk
factor
for
plays
crucial
role
mediating
pathological
effects
observed.
Understanding
multifaceted
impact
heart,
muscle,
early
detection
stratification.
knowledge
timely
implementing
management
strategies
addressing
multi-organ
involvement
pathogenesis.
Язык: Английский
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
Cardiovascular Diabetology,
Год журнала:
2025,
Номер
24(1)
Опубликована: Фев. 7, 2025
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
is
a
prevalent
and
complex
condition
limited
effective
treatments.
Endothelial
dysfunction
significant
component
of
HFpEF
pathophysiology,
glucagon-like
peptide-1
receptor
(GLP-1R)
agonists
have
shown
potential
benefits
in
improving
endothelial
function.
This
study
aims
to
explore
the
relationship
between
mechanisms
action
GLP-1R
agonists,
highlighting
their
therapeutic
benefits.
A
comprehensive
review
literature
was
conducted
examine
etiology
HFpEF,
role
dysfunction,
effects
on
function
heart
outcomes.
The
findings
indicate
that
associated
various
comorbidities,
such
as
obesity,
diabetes
mellitus,
hypertension,
which
contribute
dysfunction.
including
semaglutide
liraglutide,
demonstrated
cardioprotective
effects,
vascular
function,
reducing
inflammation,
preventing
atherosclerosis.
Clinical
trials,
STEP-HFpEF
trial,
positive
results
symptoms
physical
restrictions
patients.
present
promising
option
for
by
targeting
other
pathophysiological
mechanisms.
Further
research
needed
elucidate
precise
through
exert
establish
long-term
safety
efficacy
diverse
populations.
Язык: Английский
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots
Physiologia,
Год журнала:
2025,
Номер
5(1), С. 10 - 10
Опубликована: Фев. 27, 2025
Heart
failure
is
a
leading
cause
of
morbidity
and
mortality
worldwide
[...]
Язык: Английский
Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis
Frontiers in Endocrinology,
Год журнала:
2023,
Номер
14
Опубликована: Апрель 20, 2023
Background
and
aims
Non-alcoholic
fatty
liver
disease
(NAFLD)
is
associated
with
a
higher
risk
of
heart
failure
(HF)
than
those
without
NAFLD.
However,
the
prognostic
impact
NAFLD
in
HF
still
controversial.
This
meta-analysis
aimed
to
explore
association
between
adverse
outcomes
patients
HF.
Methods
We
searched
multiple
electronic
databases
(Embase,
PubMed,
Google
Scholar)
for
potentially
related
studies
up
June
30,
2022.
Cohort
reported
multivariable
adjusted
relative
risks
95%
confidence
intervals
(CIs)
comparing
were
included
analysis.
Results
A
total
six
involving
12,374
analysis,
median
follow-up
duration
2.5
years.
The
pooled
analysis
showed
that
significantly
increased
major
composite
(HR
1.61,
CI
1.25-2.07),
all-cause
mortality
1.66,
1.39-1.98),
hospitalization
or
re-hospitalization
1.71,
1.03-2.86).
Conclusion
worse
prognosis
Effective
screening
treatment
strategies
are
needed
improve
Язык: Английский
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
In Vivo,
Год журнала:
2023,
Номер
37(3), С. 1037 - 1046
Опубликована: Янв. 1, 2023
Non-alcoholic
fatty
liver
disease
is
a
major
cause
of
liver-related
morbidity
and
mortality.
Metformin
widely
used
medication
may
have
additional
benefits
beyond
glycemic
control.
Liraglutide,
novel
treatment
for
diabetes
obesity,
also
has
beneficial
effects
on
non-alcoholic
steatohepatitis
(NASH).
liraglutide
both
benefited
NASH
treatment.
However,
no
study
reported
the
combination
therapy
with
metformin
NASH.We
investigated
in
vivo
methionine/choline-deficient
(MCD)
diet-fed
C57BL/6JNarl
mouse
model.
Serum
triglyceride,
alanine
aminotransferase
levels
were
documented.
Histological
analysis
was
performed
according
to
activity
grade.After
metformin,
body
weight
loss
improved,
liver/body
ratio
decreased.
The
metabolic
injury
improved.
Liraglutide
alleviated
MCD-induced
hepatic
steatosis
injury.
revealed
that
reduced.Our
results
provide
evidence
anti-NASH
metformin.
offer
potential
disease-modifying
intervention
NASH.
Язык: Английский
Hypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Medicina,
Год журнала:
2024,
Номер
60(6), С. 912 - 912
Опубликована: Май 30, 2024
Over
the
last
few
years,
given
increase
in
incidence
and
prevalence
of
both
type
2
diabetes
mellitus
(T2DM)
heart
failure
(HF),
it
became
crucial
to
develop
guidelines
for
optimal
preventive
treatment
strategies
individuals
facing
these
coexisting
conditions.
In
patients
aged
over
65,
HF
hospitalization
stands
out
as
predominant
reason
hospital
admissions,
with
their
prognosis
being
associated
presence
or
absence
T2DM.
Historically,
certain
classes
glucose-lowering
drugs,
such
thiazolidinediones
(rosiglitazone),
raised
concerns
due
an
observed
increased
risk
myocardial
infarction
(MI)
cardiovascular
(CV)-related
mortality.
response
concerns,
regulatory
agencies
started
requiring
CV
outcome
trials
all
novel
antidiabetic
agents
[i.e.,
dipeptidyl
peptidase-4
inhibitors
(DPP-4
inhibitors),
glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs),
sodium-glucose
cotransporter-2
(SGLT2is)]
aim
assess
safety
drugs
beyond
glycemic
control.
This
narrative
review
aims
address
current
knowledge
about
impact
used
T2DM
on
prevention,
prognosis,
outcome.
Язык: Английский
The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis
ESC Heart Failure,
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 29, 2024
Abstract
There
is
a
need
to
address
the
evidence
gap
regarding
in‐hospital
administration
of
sacubitril/valsartan
in
acute
myocardial
infarction
patients.
After
searching
MEDLINE,
Google
Scholars
and
Scopus,
random‐effects
meta‐analysis
randomized
controlled
trials
comparing
angiotensin
receptor‐neprilysin
inhibitors
(ARNis)
versus
standard
therapy
patients
with
reduced
heart
failure
due
was
performed.
The
primary
outcome
major
adverse
cardiovascular
events.
All‐cause
mortality,
cardiac
death,
rehospitalization
for
failure,
non‐fatal
(MI),
changes
left
ventricular
ejection
fraction,
volumes,
N
terminal
pro
brain
natriuretic
peptide
events
were
secondary
endpoints.
Nine
studies
(eight
one
echo‐substudy)
total
6597
individuals
(angiotensin‐converting
enzyme
inhibitor/angiotensin
receptor
blocker:
3300
vs.
ARNis:
3297
patients)
included
quantitative
analysis.
Median
follow‐up
6
months.
Patients
receiving
an
coadministration
ARNi
had
lower
risk
event
[odds
ratio
(OR)
0.45,
95%
confidence
interval
(CI)
0.32–0.63,
P
<
0.0001]
rate
repeat
(OR
0.40,
CI
0.26–0.62,
0.0001),
compared
regimen.
Additionally,
ventricle
volumes
significantly
group
[left
end‐diastolic
volume,
mean
difference
(MD)
11.48
mL,
6.10–16.85,
0.0001;
end‐systolic
MD
7.09
2.89–11.29,
=
0.0009]
significant
change
fraction
(MD
3.07,
1.61–4.53,
therapy.
No
differences
observed
terms
all
cause
peptide.
Higher
rates
iatrogenic
hypotensive
1.42,
1.26–1.60,
value
0.00001).
In
related
ARNis
associated
re‐hospitalization
as
well
remodelling,
but
higher
Язык: Английский
Exercise-mediated epigenetic modifications in cardiovascular diseases
Epigenomics,
Год журнала:
2024,
Номер
17(3), С. 179 - 191
Опубликована: Дек. 30, 2024
Cardiovascular
diseases
(CVDs)
represent
a
prominent
contributor
to
global
morbidity
and
mortality
rates,
with
projections
indicating
rise
in
this
burden
due
population
aging.
While
extensive
research
has
underscored
the
efficacy
of
exercise
mitigating
risk
CVDs,
precise
mechanisms,
particularly
within
realm
epigenetics,
remain
nascent.
This
article
delves
into
cutting-edge
concerning
exercise-induced
epigenetic
alterations
their
impact
on
CVDs.
Initially,
we
examine
cardiac
implications
stemming
from
influences
across
varying
intensities.
Subsequently,
our
focus
shifts
toward
delineating
mechanisms
governing
DNA
methylation,
lactylation
modifications,
N6-methyladenosine
(m6A)
RNA
alongside
addressing
associated
challenges
outlining
prospective
directions.
These
findings
suggest
that
exercise-mediated
modifications
offer
promising
therapeutic
potential
for
prevention
comorbidity
management
However,
heterogeneity
tissue
specificity
these
effects
necessitate
more
targeted
unlock
full
potential.
Язык: Английский
Metabolic Dysfunction-Associated Steatotic Liver Disease and Heart Failure with Preserved Ejection Fraction: A Bidirectional Relationship with Clinical and Therapeutic Implications
Deleted Journal,
Год журнала:
2024,
Номер
unknown, С. 1 - 17
Опубликована: Сен. 18, 2024
Background:
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
increasingly
prevalent
and
the
most
common
cause
of
chronic
in
western
world.
It
considered
hepatic
manifestation
metabolic
syndrome
ultimately
leads
to
cardiovascular
diseases,
which
are
leading
death.
Heart
failure
with
preserved
ejection
fraction
(HFpEF)
appears
be
a
complication
MASLD
and,
conversely,
seems
exacerbate
its
severity.
This
review
focuses
on
pathophysiological
association
between
HFpEF,
as
well
their
clinical
therapeutic
implications.
Summary:
The
connection
HFpEF
intricate
bidirectional,
involving
several
mechanisms,
such
insulin
resistance,
overactivation
renin-angiotensin-aldosterone
sympathetic
nervous
systems,
systemic
inflammation,
gut
dysbiosis.
an
independent
risk
factor
for
diastolic
dysfunction
increasing
hospitalization
death
those
established
heart
failure.
Conversely,
exacerbates
severity
MASLD.
Screening
fibrosis
should
conducted
stable
euvolemic
patients
utilizing
ultrasonography
Fibrosis-4
index.
performed
measurement
natriuretic
peptides;
however,
these
may
have
lower
sensitivity
echocardiography
needed.
Therapeutic
strategies
both
limited,
but
certain
interventions
studied
also
benefit
system.
Lifestyle
interventions,
adherence
Mediterranean
diet
weight
loss,
proven
beneficial
diseases.
Sodium-glucose
cotransporter
2
inhibitors
(SGLT2i)
incretin
mimetics
show
promise
treating
conditions
synergistic
effects.
Key
Messages:
increases
incident
worsens
prognosis
HFpEF.
Given
high
prevalence
screening
crucial.
begin
peptides
when
there
suspicion.
SGLT2i
glucagon-like
peptide-1
receptor
agonists
offer
benefits
Язык: Английский